"FDA Awards First Priority Review Vouchers to Nine Pharma Innovators"

The Food and Drug Administration awarded its first nine priority review vouchers to companies like Sanofi and Regeneron Pharmaceuticals, accelerating the approval process for critical medicines.

• The Food and Drug Administration launched its priority review voucher program in June 2023, allowing expedited approval for medicines addressing U.S. national priorities.
• Companies including Regeneron Pharmaceuticals and Sanofi received the first nine vouchers, which could shorten approval times from the typical 10 to 12 months to just one or two months.
• The program emphasizes the importance of innovative therapies, such as gene therapy for hearing loss, in meeting pressing health needs in the United States.